The correlation of thymidine phosphorylase activity with the expression of interleukin 1α, interferon α and interferon γ in human colorectal carcinoma

doi:10.1016/0304-3835(95)03865-T

Cancer Letters

Volume 95, Issues 1–2, 16 August 1995, Pages 57-62

https://doi.org/10.1016/0304-3835(95)03865-T Get rights and content

Abstract

Thymidine phosphorylase (dThdPase) is an angiogenic enzyme and seems to be related to an angiogenesis in human colorectal carcinoma. The incidence of dThdPase-positive cells was significantly correlated with microvessel count in 21 human colorectal carcinomas. Interleukin 1α (IL-1α), tumor necrosis factor α (TNF-α), interferon α (IFN-α) interferon γ (IFN-γ) induce dThdPase activity in human cancer cell lines. To study whether this phenomenon occurs in the human colorectal carcinomas, we examined the correlation between dThdPase activity and the expression levels of IL-1α, TNF-α, IFN-α and IFN-γ in colorectal carcinoma tissues. dThdPase activity was assayed by the methods of Friedkin and Robert, and the expression level of IL-1α, TNF-α, IFN-α and IFN-γ was determined by ELISA. dThdPase activity was significantly correlated with the amount of IL-1α (n = 19, r = 0.347, P = 0.0001), INF-α (n = 18, r = 0.717, P = 0.0008), and IFN-γ (n = 4, r = 0.9777, P = 0.0234) in human colorectal carcinomas. However, the dThdPase activity was not correlated with the amount of TNF-α (n = 21, r = 0.235, P = 0.2682). These results suggested that the expression levels of IL-1α, IFN-α and IFN-γ are correlated with dThdPase activity in human colorectal carcinomas and that these cytokines may cause angiogenesis by inducing the expression of dThdPase.

References (21)

M.A. Bradford
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding
Anal. Biochem.
(1976)
M. Friedkin et al.
The enzymatic synthesis of nucleosides
J. Biol. Chem.
(1954)
R.C. Gallo et al.
The enzymatic mechanisms for deoxythymidine synthesis in human leukocytes
J. Biol. Chem.
(1967)
T.A. Krenitsky
Pentosyl transfer mechanisms of the mammalian nucleoside phosphorylases
J. Biol. Chem.
(1968)
H.T. Tevaearai et al.
Interactions of interferon-α_2a with 5′-deoxy-5-fluorouridine in colorectal cancer cells in vitro
Eur. J. Cancer
(1992)
K. Usuki et al.
Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity
Biochem. Biophys. Res. Commun.
(1992)
M. Zimmerman et al.
Deoxyribosyl transfer
J. Biol. Chem.
(1964)
R.D. Armstrong et al.
5′-Deoxy-5-fluorouridine; cellular metabolism of a new fluoropyridine, a novel fluoropyridine with antineophastic activity
R.D. Armstrong et al.
Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyridine
Cancer Res.
(1980)
R.D. Armstrong et al.
Cytotoxic activity of 5′-deoxy-5-fluorouridine in cultured human tumors
Cancer Treat. Rep.
(1983)

There are more references available in the full text version of this article.

Cited by (28)

Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment
2023, Life Sciences
The interleukin-1 receptor antagonist (IL-1Ra) is an anti-inflammatory cytokine and a naturally occurring antagonist of the IL-1 receptor. It effectively counteracts the IL-1 signaling pathway mediated by IL-1α/β. Over the past few decades, accumulating evidence has suggested that IL-1 signaling plays an essential role in tumor formation, growth, and metastasis. Significantly, anakinra, the first United States Food and Drug Administration (FDA)-approved IL-1Ra drug, has demonstrated promising antitumor effects in animal studies. Numerous clinical trials have subsequently incorporated anakinra into their cancer treatment protocols. In this review, we comprehensively discuss the research progress on the role of IL-1 in tumors and summarize the significant contribution of IL-1Ra (anakinra) to tumor immunity. Additionally, we analyze the potential value of IL-1Ra as a biomarker from a clinical perspective. This review is aimed to highlight the important link between inflammation and cancer and provide potential drug targets for future cancer therapy.
IL-1α and colorectal cancer pathogenesis: Enthralling candidate for anti-cancer therapy
2021, Critical Reviews in Oncology/Hematology
Citation Excerpt :
Interestingly, IL-1α in combination with other cytokines such as interferon γ (IFN- γ) and tumour necrosis factor α (TNF- α) induces the expression of iNOS and production of NO (Nam et al., 2015, 2007). Research have shown a strong correlation between the levels of IL-1α and dThdPase in human colorectal carcinomas (Takebayashi et al., 1995). dThdPase is an enzyme that catalyses the reaction of thymidine (TdR) to deoxyribose-1-phosphate (dR-1-P) and thymine, which allows for the formation of deoxyribose (dR); the molecule responsible for the angiogenic effects of dThdPase (Bijnsdorp et al., 2010).
Inflammation has been well-established as a hallmark of colorectal cancer (CRC). Interleukin-1 alpha (IL-1α) is one of the primary inflammatory mediators driving the pathogenesis of inflammation-associated CRC. This systematic review presents the roles of IL-1α in the pathogenesis of the disease. Bibliographic databases PubMed, Science Direct, Scopus and Web of Science were systematically searched for articles that addresses the relationship between IL-1α and colorectal cancer. We highlighted various mechanisms by which IL-1α promotes the pathogenesis of CRC including enhancement of angiogenesis, metastasis, resistance to therapy, and inhibition of tumour suppressive genes. We also discussed the potential mechanisms by which IL-1α expression is induced or secreted in various studies. Beyond these, the systematic review also highlights several potential therapeutic strategies which should be further explored in the future; to target IL-1α and/or its associated pathways; paving our way in finding effective treatments for CRC patients.
The synthesis of possible transition state analogue inhibitors of thymidine phosphorylase
2015, Tetrahedron Letters
Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using <sup>16</sup>O/<sup>18</sup>O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS
2009, Molecular and Cellular Proteomics
Citation Excerpt :
The TYPH protein is overexpressed in a wide variety of solid tumors. This protein can be induced by several cytokines, including IFNs, and contributes to angiogenesis (79, 80). In addition, STAT1 is a key regulator of the IFN signaling pathway and is known to be overexpressed in OSCC tissues (70, 81).
Oral squamous cell carcinoma (OSCC) remains one of the most common cancers worldwide, and the mortality rate of this disease has increased in recent years. No molecular markers are available to assist with the early detection and therapeutic evaluation of OSCC; thus, identification of differentially expressed proteins may assist with the detection of potential disease markers and shed light on the molecular mechanisms of OSCC pathogenesis. We performed a multidimensional ¹⁶O/¹⁸O proteomics analysis using an integrated ESI-ion trap and MALDI-TOF/TOF MS system and a computational data analysis pipeline to identify proteins that are differentially expressed in microdissected OSCC tumor cells relative to adjacent non-tumor epithelia. We identified 1233 unique proteins in microdissected oral squamous epithelia obtained from three pairs of OSCC specimens with a false discovery rate of <3%. Among these, 977 proteins were quantified between tumor and non-tumor cells. Our data revealed 80 dysregulated proteins (53 up-regulated and 27 down-regulated) when a 2.5-fold change was used as the threshold. Immunohistochemical staining and Western blot analyses were performed to confirm the overexpression of 12 up-regulated proteins in OSCC tissues. When the biological roles of 80 differentially expressed proteins were assessed via MetaCore™ analysis, the interferon (IFN) signaling pathway emerged as one of the most significantly altered pathways in OSCC. As many as 20% (10 of 53) of the up-regulated proteins belonged to the IFN-stimulated gene (ISG) family, including ubiquitin cross-reactive protein (UCRP)/ISG15. Using head-and-neck cancer tissue microarrays, we determined that UCRP is overexpressed in the majority of cheek and tongue cancers and in several cases of larynx cancer. In addition, we found that IFN-β stimulates UCRP expression in oral cancer cells and enhances their motility in vitro. Our findings shed new light on OSCC pathogenesis and provide a basis for the future development of novel biomarkers.
Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo
1999, Cancer Letters
5′-Deoxy-5-fluorouridine (5′-dFUrd) is a prodrug of 5-fluorouracil (5-FUra) activated by pyrimidine nucleoside phosphorylase (PyN Pase), mainly by uridine phosphorylase (Urd Pase) in rodents and by thymidine phosphorylase (TdR Pase) in humans, which is preferentially located in tumor tissues compared to normal tissues. It has been reported that PyN Pase is induced by cytokines such as tumor necrosis factor (TNF), interleukin-1α (IL-1α) and interferon (IFN). Thymosin is a glycoprotein extract obtained from the calf thymus and is a potent immunopotentiating preparation. In this study, the antiproliferative activity of 5′-dFUrd used in combination with thymosin fraction 5 (TF5) was investigated in mouse bladder cancer cell line MBT-2 in vitro and in vivo. In vitro TF5 enhanced the activity of 5′-dFUrd by up to 4.11-fold, whereas the activity of other cytostatics such as 5-FUra, mitomycin C, adriamycin, cis-platinum, etoposide, vinblastine and methrotrexate was not changed. In vivo when the effects of combination therapy with 5′-dFUrd and TF5 in C3H/HeN mice implanted with MBT2 were studied, tumor growth was not suppressed by TF5 alone while tumor growth was suppressed to some degree by 5′-dFUrd alone. However, tumor growth suppression was enhanced when 5′-dFUrd was used in combination with TF5. In order to investigate this mechanism, Urd Pase in MB2 was measured, and it was found that TF5 increased enzyme activity by up to 1.8-fold in MBT2. This increased susceptibility might be a result of the induction of Urd Pase, which is the essential enzyme for the conversion of 5′-dFUrd to 5-FUra. These results suggested that the therapeutic benefit of 5′-dFUrd would be improved by its use in combination with TF5 and the modulation of converting enzymes for antitumor prodrugs could be a novel therapeutic strategy for treating human cancers.
Thymidine phosphorylase: Its role in sensitivity and resistance to anticancer drugs
1999, Drug Resistance Updates
Thymidine phosphorylase (TP) is an angiogenic enzyme present in normal tissues. Increased levels are found in many tumors, in stromal cells, tumor cells or both. High tumor TP levels may confer a poor prognosis. Cytokines (including interferons), tissue hypoxia and low pH increase TP levels. The influence of tumor TP on fluoropyrimidine toxicity is variable, but capecitabine is a prodrug of fluorouracil that requires activation by TP and hence may have a higher therapeutic index than other fluoropyrimidines. Folate-based thymidylate synthase inhibitors may also be more effective in tumors with a high TP because of increased degradation of endogenous thymidine.

View all citing articles on Scopus

View full text

Article preview

Cancer Letters

Abstract

References (21)

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding

Anal. Biochem.

The enzymatic synthesis of nucleosides

J. Biol. Chem.

The enzymatic mechanisms for deoxythymidine synthesis in human leukocytes

J. Biol. Chem.

Pentosyl transfer mechanisms of the mammalian nucleoside phosphorylases

J. Biol. Chem.

Interactions of interferon-α_2a with 5′-deoxy-5-fluorouridine in colorectal cancer cells in vitro

Eur. J. Cancer

Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity

Biochem. Biophys. Res. Commun.

Deoxyribosyl transfer

J. Biol. Chem.

5′-Deoxy-5-fluorouridine; cellular metabolism of a new fluoropyridine, a novel fluoropyridine with antineophastic activity

Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyridine

Cancer Res.

Cytotoxic activity of 5′-deoxy-5-fluorouridine in cultured human tumors

Cancer Treat. Rep.

Cited by (28)

Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment

IL-1α and colorectal cancer pathogenesis: Enthralling candidate for anti-cancer therapy

The synthesis of possible transition state analogue inhibitors of thymidine phosphorylase

Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using <sup>16</sup>O/<sup>18</sup>O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS

Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo

Thymidine phosphorylase: Its role in sensitivity and resistance to anticancer drugs